Summary 2,3,5-Trimethyl-6-(3-pyridylmethyl)1,4-benzoquinone is an effective inhibitor of the growth of established murine adenocarcinomas (MACs) and is shortly to enter clinical investigation. When administered to mice bearing the MAC16 tumour, CV-6504 rapidly disappeared from the plasma and tissues and there was an accumulation of the sulphate and glucuronide metabolites. After 24 h, the concentration of free CV-6504 in the tumour (3.3 gM) was higher than that in the liver (0.24 /M) and equal to the IC50 value for the inhibition of the growth of MAC16 cells in vitro (3 pM). Products of metabolism of the polyunsaturated fatty acids (PUFAs), arachidonic (AA) or linoleic (LA) acid, through the lipoxygenase pathways have been shown to stimulate cell proliferation (Bandyopadhyay et al., 1988) and may also act as intermediaries in the mitogenic signalling by growth factors, such as epidermal growth factor (EGF) (Glasgow and Eling, 1990) . Linoleic acid has been shown to induce DNA synthesis, c-fos, c-jun and c-myc mRNA expression and mitogen-activated protein kinase activation in vascular smooth muscle cells, and this effect was blocked by nordihydroguairetic acid, a potent inhibitor of the lipoxygenase system (Rao et al., 1995) . Lipoxygenase inhibitors have also been shown to inhibit the growth of both rat (Lee and Ip, 1992) and mouse (Buckman et al., 1991) mammary tumour cells and HL60 human leukaemia cells (Simon et al., 1992) .
Products of metabolism of the polyunsaturated fatty acids (PUFAs), arachidonic (AA) or linoleic (LA) acid, through the lipoxygenase pathways have been shown to stimulate cell proliferation (Bandyopadhyay et al., 1988) and may also act as intermediaries in the mitogenic signalling by growth factors, such as epidermal growth factor (EGF) (Glasgow and Eling, 1990) . Linoleic acid has been shown to induce DNA synthesis, c-fos, c-jun and c-myc mRNA expression and mitogen-activated protein kinase activation in vascular smooth muscle cells, and this effect was blocked by nordihydroguairetic acid, a potent inhibitor of the lipoxygenase system (Rao et al., 1995) . Lipoxygenase inhibitors have also been shown to inhibit the growth of both rat (Lee and Ip, 1992) and mouse (Buckman et al., 1991) mammary tumour cells and HL60 human leukaemia cells (Simon et al., 1992) .
Our own studies have identified the 5-lipoxygenase inhibitor (Ohkawa et al., 1991a) , 2,3,5-trimethyl-6-(3-pyridylmethyl)1,4-benzoquinone (CV-6504), as an effective inhibitor of the growth of established murine adenocarcinomas (MAC) in vivo with a therapeutic index of at least 10 (Hussey et al., 1996) . Such tumours are generally refractory to standard cytotoxic agents, suggesting a novel mechanism of tumour inhibition, and this agent is shortly to undergo clinical evaluation.
CV-6504 undergoes rapid reduction by two-electron donating enzymes, such as DT-diaphorase, and the resulting hydroquinone inhibits both 5-lipoxygenase activity and lipid peroxidation on the basis of its antioxidant ability (Ohkawa et al., 199 lb) by reducing the ferric iron in the active site of the enzyme to the ferrous (resting state). Studies on the metabolism of CV-6504 by mice, rats, dogs and monkeys indicate reduction of the quinone ring and subsequent conjugation to yield the 1-and 4-glucuronides and the corresponding sulphates (Takeda Chemical Co., personal communication). These conjugates would not be capable of inhibiting 5-lipoxygenase by the suggested mechanism.
In the present study the tumour and tissue levels of CV- Concentration (gM) Figure 1 The effect of CV-6504 (x) and (a) CV-6504-1-sulphate (-) and 4-sulphate (0) Figure 1 . While free CV-6504 effectively inhibited cell growth with an IC50 value of 3 gM, none of the metabolites were effective growth inhibitors at concentrations up to 100 pLM. The effect of the four metabolites and free CV-6504 on the growth of the MAC13 tumour in vivo is shown in Figure 2 (a and b) . When administered daily at a dose of 50 mg kg-', the anti-tumour activity of the glucuronide and sulphate conjugates was similar to that obtained with free CV-6504 administered orally at 5 mg kg-1 day -'. The antitumour activity of the 4-glucuronide and 1-sulphate was slightly reduced in comparison with the 1-glucuronide and 4-sulphate, although this was not significant. This suggests that the MAC13 tumour may also be capable of enzymatic deconjugation of the glucuronide and sulphate metabolites. Broken cell preparations of the MAC13 tumour were capable of liberating 18 jug phenolphthalein per 30 min per mg protein from 0.4 mm phenolphthalein glucuronide and 30 nmol sulphate per 30 min per mg protein from 1.78 mM p-nitrocatechol sulphate at pH 5.0. Thus anti-tumour activity might be expected to be higher in those tumours expressing glucuronidase and sulphatase.
The effect of CV-6504 and the 1-sulphate and 4-glucuronide metabolites on the metabolism of AA in MAC1 3 tumours ex vivo is shown in Figure 3 (a and b) . There was rapid metabolism of AA with fairly equal distribution along the pathways leading to the formation of 5-, 11-, 12-and 15-hydroxyeicosatetraenoic acids (HETEs). After incubation with 10 jiM CV-6504 for 30 m-, 5-, 11-, 12-and 15-HETE production, as well as the total unmetabolised AA, was significantly decreased. The percentage reduction in formation of 100 gM CV-6504 4-glucuronide also significantly reduced 5-, 11-and 12-HETE production by 30 min and 15-HETE production by 1 h.
Discussion
We have previously shown CV-6504 to exert marked antitumour activity in the murine tumour models, MAC16 and MAC13, passaged in NMRI mice (Hussey et al., 1996) . CV-6504 is known to be rapidly removed from the circulation and converted into the glucuronide and sulphate conjugates, which are not effective lipoxygenase inhibitors and might not be expected to exert anti-tumour activity. (Setty et al., 1987) , which is mediated by inhibition of diacyl glycerol kinase and the concomitant accumulation of cellular diacylglycerol. 12(S)-HETE has also been shown to promote wound healing of injured microvascular endothelial cells by increasing DNA synthesis more than 4-fold (Tang et al., 1995) . In neonatal rat lens epithelial cells it has been suggested that 12(S)-HETE may mediate EGF/insulin-stimulated DNA synthesis by regulating protooncogene expression (Lysz et al., 1994) , and that it may augment the invasiveness of rat prostatic tumour (Liu et al., 1994b) . Thus, inhibition of 12-and/or 15-HETE formation may be expected to inhibit tumour cell growth and metastasis.
In the present study, CV-6504 has been shown to inhibit the production of 5-, 12-and 15-HETE in MAC13 tumour cells ex vivo. Both the 12-and 15-lipoxygenase pathways are inhibited, despite the targeting of this compound to 5-lipoxygenase (Ohkawa et al., 1991a) , and the inhibitory effect on 12-and 15-lipoxygenase exceeded that of 5-lipoxygenase as measured by HETE formation. A similar effect has been observed with the PUFA eicosapentaenoic acid (EPA), which also exerts a marked antiproliferative effect on the chemounresponsive MAC16 tumour (Hudson et al., 1993) . This agent has also been shown to exert an anti-tumour effect against human breast cancer cells xenotransplanted into nude mice by reducing the tumour concentration of 12-and 15-HETE, while the level of 5-HETE was unaffected (Rose et al., 1995) . Both CV-6504 1-sulphate and 4-glucuronide inhibited formation of 5-, 12-and 15-HETE formation in MAC13 tumour cells ex vivo in a time-dependent manner, suggesting conversion of these metabolites to free CV-6504. Inhibition of 12-and 15-HETE production occurred before inhibition of 5-HETE production. Thus, suppression of 12-and/or 15-lipoxygenase pathways may be most important for inhibition of tumour growth.
These results suggest that CV-6504 may inhibit tumour growth as a result of the ability to inhibit 12-and/or 15-HETE production. Human tumours with a dependence on the 12-and 15-lipoxygenase pathways for growth may also be sensitive to this agent.
